Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859 · Recruiting

Last updated 2026-05-28

This clinical trial tests whether the medication tirzepatide can slow the buildup of fatty deposits in the heart’s arteries in adults with type 2 diabetes and existing heart disease.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind health-services study

Participants 120 people Planned (estimated).

Who can join Ages 40–80 · all sexes

Timeline Started 2024-01 · est. completion 2026-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05708859 ↗

Description as written by the study sponsor.

A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.

Treatments tested

Tirzepatide also known as Mounjaro Drug

Tirzepatide 15mg Subcutaneous Solution
Placebo Drug

Volume matched Subcutaneous Solution

Main thing measured	Reduction of total non-calcified coronary plaque volume
Sponsor	Matthew J. Budoff
Conditions studied	Type II Diabetes, Atherosclerosis
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05708859 ↗